Treatment of chronic GVHD with extracorporeal photochemotherapy

Bojanić, Ines; Seiwerth, Ranka Serventi; Ćepulić, Branka Golubić; Mazić, Sanja; Lukić, Martina; Raos, Miljenko; Plenković, Fini; Golemović, Mirna; Dubravčić, Klara; Perković, Sanja; Batinić, Danica; Labar, Boris

doi:10.1016/j.transci.2013.02.033

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second study, 6 patients underwent 13–127 ECP procedures (between 6 months and 5 years): all patients reported decreased skin or mucosal involvement. However, the outcome criteria and the skin scores used were not described [9]. …”

Section: Discussionmentioning

confidence: 99%

Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease

et al. 2018

View full text Add to dashboard Cite

Background: Extracorporeal photopheresis (ECP) is a second-line therapy for steroid-refractory chronic graft-versus-host disease (cGVHD). Objective: We describe the long-term efficacy and tolerability of ECP according to the cutaneous phenotype of cGVHD and report on the reduced need for immunosuppressant drugs in this setting. Patients and Methods: Fourteen patients (8 females) with cutaneous and/or mucosal cGVHD, treated with ECP between October 2010 and May 2016 within a single center, were included. Final analyses included patients who had received ECP for at least 12 months. We prospectively evaluated the efficacy of ECP using lesion-specific clinical scores and by recording changed doses of systemic immunosuppressants. Results: Of the 14 patients, sclerotic skin lesions were present in 10 (71%). The mRODNAN score decreased in all patients from month 9 onwards, with 40 and 77% reductions at 12 and 36 months, respectively. Six patients (43%) presented with cutaneous lichenoid lesions: this score was reduced in all patients by month 3, reaching a 93% reduction by month 12. Five patients (36%) experienced oral mucosal lichenoid lesions: these scores were decreased by 55% at month 12 and by 100% by month 33. The use of systemic immunosuppressants was reduced in all patients; 4 patients could stop all immunosuppressant drugs after 2 years. ECP was stopped in 3 patients after a complete response. No major ECP-associated adverse effects were observed. Discussion and Conclusion: ECP was an effective long-term therapy for oral and cutaneous cGVHD: consequently, dose levels of therapeutic immunosuppression could be reduced.

show abstract

Section: Discussionmentioning

confidence: 99%